Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.65 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.63 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.63 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28298203 | 0.89 | CHRM2 (0.79) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| SCHEMBL30573473 | 0.86 | CHRM2 (0.70) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| SCHEMBL5319031 | 0.85 | CHRM2 (0.65) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| SCHEMBL11225310 | 0.84 | CHRM2 (0.63) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| SCHEMBL20595548 | 0.83 | CHRM2 (0.70) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| SCHEMBL11403125 | 0.83 | CHRM2 (0.62) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| SCHEMBL9089518 | 0.82 | CHRM2 (0.60) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| SCHEMBL11928962 | 0.81 | CHRM2 (0.72) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| SCHEMBL9452813 | 0.81 | MEN1 (0.61) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| Hydrochloric Acid SCHEMBL30087523 | 0.80 | APOBEC3A (0.73) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007096251-A1 | INHIBITORS OF CPT IN THE CENTRAL NERVOUS SYSTEM AS ANTIDIABETIC AND/OR ANTI-OBESITY DRUGS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-08-30 | — | — | WO | disclosed |
| EP-1197485-B1 | Cyclobuten-dione derivatives for use in the treatment of artherosclerosis | SERVIER LAB (FR) | 2004-08-11 | — | — | EP | disclosed |
| US-6696469-B2 | FOR TREATMENT OF DISEASES OR PATHOLOGICAL CONDITIONS IN WHICH ENDOTHELIAL DYSFUNCTION IS KNOWN; ATHEROSCLEROSIS, DYSLIPIDAEMIA, DIABETES | LES LABORATOIRES SERVIER (FR) | 2004-02-24 | — | — | US | disclosed |
| US-20020065419-A1 | Cyclobutenedione compounds | LES LABORATOIRES SERVIER (FR) | 2002-05-30 | — | — | US | disclosed |
| EP-1197485-A1 | Cyclobuten-dione derivatives for use in the treatment of artherosclerosis | Les Laboratoires Servier (FR) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065419-A1 | Cyclobutenedione compounds | NR3C2, NR5A1, CYP11B1 | CHRM2 1881/4885OPRK1 859/4885CYP1A2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.